Skip Navigation

Cardiovascular Research 2002 53(2):372-381; doi:10.1016/S0008-6363(01)00487-4
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kiriazis, H.
Right arrow Articles by Kranias, E. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiriazis, H.
Right arrow Articles by Kranias, E. G
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2001, European Society of Cardiology

Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis

Helen Kiriazisa, Yoji Satob, Vivek J Kadambic, Albrecht G Schmidta,1, Michael J Gersta, Brian D Hoitd and Evangelia G Kraniasa,*

aDepartment of Pharmacology and Cell Biophysics, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH 45267-0575, USA
bDivision of Xenobiotics, Metabolism and Disposition, National Institute of Health Sciences, Setagaya, Tokyo 158-8501, Japan
cDepartment of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, MA 02139, USA
dDivision of Cardiology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH 44106-5029, USA

litsa.kranias{at}uc.edu

* Corresponding author. Tel.: +1-513-5582-377; fax: +1-513-5582-269

Objective: To determine whether the hyperdynamic phospholamban-knockout hearts are capable of withstanding a chronic aortic stenosis. Methods: The transverse section of the aorta was banded in phospholamban-knockout and their isogenic wild-type mice, which were followed with echocardiography in parallel, along with sham-operated mice, before and at 2.5, 5 and 10 weeks after surgery. Results: Cardiac decompensation was evidenced by the presence of lung congestion in some banded knockouts and wild-types, giving rise to a subset of non-failing and failing hearts within each group. The incidence of heart failure was not genotype-dependent but rather associated with higher heart rates before surgery. The development of left ventricular hypertrophy was similar between knockouts and wild-types and longitudinal assessment of end-diastolic dimension indicated progressive increases after banding, with a greater dilation in failing mice. Fractional shortening was reduced in failing knockouts and wild-types to a similar degree, with an earlier onset in the knockouts. In addition, fractional shortening was decreased in non-failing knockouts but not wild-types. Ejection times shortened after aortic banding particularly for failing hearts. Assessment of the SR Ca2+-ATPase protein levels indicated similar downregulation for failing knockouts and wild-types, while the phospholamban levels were not significantly altered in wild-types. Conclusion: The hyperdynamic phospholamban-knockout hearts are able to compensate against a sustained aortic stenosis similar to wild-types.

KEYWORDS Ca-pump; Heart failure; Hypertrophy; SR (function); Ventricular function


1 Current address: Zentrum Innere Medizin, Abteilung Kardiologie und Pneumologie, Georg-August-Universität Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Vinet, P. Rouet-Benzineb, X. Marniquet, N. Pellegrin, L. Mangin, L. Louedec, J.-L. Samuel, and J.-J. Mercadier
Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H352 - H360.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
S. R. Houser and J. D. Molkentin
Does Contractile Ca2+ Control Calcineurin-NFAT Signaling and Pathological Hypertrophy in Cardiac Myocytes?
Sci. Signal., June 24, 2008; 1(25): pe31 - pe31.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. E. Vinge, P. W. Raake, and W. J. Koch
Gene Therapy in Heart Failure
Circ. Res., June 20, 2008; 102(12): 1458 - 1470.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. O'Rourke
The Ins and Outs of Calcium in Heart Failure
Circ. Res., June 6, 2008; 102(11): 1301 - 1303.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. Y. Oudit, Z. Kassiri, J. Zhou, Q. C. Liu, P. P. Liu, P. H. Backx, F. Dawood, M. A. Crackower, J. W. Scholey, and J. M. Penninger
Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress
Cardiovasc Res, June 1, 2008; 78(3): 505 - 514.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Brickson, D. P. Fitzsimons, L. Pereira, T. Hacker, H. Valdivia, and R. L. Moss
In vivo left ventricular functional capacity is compromised in cMyBP-C null mice
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1747 - H1754.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
X.-J. Du, X.-M. Gao, H. Kiriazis, X.-L. Moore, Z. Ming, Y. Su, A. M. Finch, R. A. Hannan, A. M. Dart, and R. M. Graham
Transgenic {alpha}1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival
Cardiovasc Res, September 1, 2006; 71(4): 735 - 743.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
H. Nakayama, B. J. Wilkin, I. Bodi, and J. D. Molkentin
Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart
FASEB J, August 1, 2006; 20(10): 1660 - 1670.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
B. D. Hoit
Echocardiographic Characterization of the Cardiovascular Phenotype in Rodent Models
Toxicol Pathol, January 1, 2006; 34(1): 105 - 110.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. C. Champion
Targeting Protein Phosphatase 1 in Heart Failure
Circ. Res., April 15, 2005; 96(7): 708 - 710.
[Full Text] [PDF]


Home page
Circ. Res.Home page
A. Pathak, F. del Monte, W. Zhao, J.-E. Schultz, J. N. Lorenz, I. Bodi, D. Weiser, H. Hahn, A. N. Carr, F. Syed, et al.
Enhancement of Cardiac Function and Suppression of Heart Failure Progression By Inhibition of Protein Phosphatase 1
Circ. Res., April 15, 2005; 96(7): 756 - 766.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A.-S. Armand and L. J De Windt
Calcium cycling in heart failure: how the fast became too furious
Cardiovasc Res, June 1, 2004; 62(3): 439 - 441.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. E. J. Schultz, B. J. Glascock, S. A. Witt, M. L. Nieman, K. J. Nattamai, L. H. Liu, J. N. Lorenz, G. E. Shull, T. R. Kimball, and M. Periasamy
Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity
Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1146 - H1153.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. R. Houser and K. B. Margulies
Is Depressed Myocyte Contractility Centrally Involved in Heart Failure?
Circ. Res., March 7, 2003; 92(4): 350 - 358.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.